Cobra Signs Contract with Replikun Biotech for Novel Gene Therapy Approach

Cobra Biomanufacturing Plc. (AIM : CBF) has signed a contract with the Australian company Replikun Biotech to support the development of an innovative gene therapy method.

Cobra will construct and establish a packaging cell line producing KUN-GMCSF, a potent and novel gene therapy system for the treatment of cancer.

Commenting on the contract, David Thatcher, CEO at Cobra, said: “We are delighted to engage with Replikun for this exciting project. It is a valuable endorsement of our ability to work with novel viruses and vaccines, and also demonstrates our continued expansion within the Australian biopharmaceutical market." Dr Shane Storey, CEO at Replikun, said, “We are very impressed with Cobra’s expertise in the manufacture of novel viruses and vector systems and are confident that they will deliver the cell lines in time and with the highest quality as required for our KUN-GMCSF program.”